Tagged with France

Pharma The General Manager of LEEM talks about the association’s strategy based on three key points, innovation, attractiveness and efficiency; how the Mediator affair has placed a question mark on the championing of the pharma industry as a national asset; why both France and Europe are at turning point and what…

innovation Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research industry and stresses the importance of knowledge-sharing for success.   What have been some of the most important changes made…

ireland Mr. Mazeman, can you please begin by offering a brief overview of your career to date? I am a French pharmacist by training, with expertise in pharmacology. I have worked for Servier for my entire career. I started in the industry as a medical representative for the company. I went…

Nycomed France Nycomed lost an important patent with Pantoprazole in the middle of 2009, which has undoubtedly warranted some restructuring. What has been the impact of this loss on business in France, and how are you preparing for the future? Losing exclusivity with Pantoprazole is huge as it was 70% of our…

Bristol-Myers Squibb France BMS recently announced divesting from their facilities in Epernon and Meymac but at the same time reinforcing manufacturing in Agen. Could you speak to strategy of this restructuring within France and what it means for the future? In the larger context of the industry, we are at a crossroads where…

Novartis France You worked for many years in emerging markets, especially in Latin America, but also in neighbor countries such as Spain. How these previous experiences in very different markets can now help you direct the world’s third largest pharmaceutical market? Experiencing different patterns, trends and types of businesses gives you a…

Teva France We have had the chance to interview a number of Teva’s subsidiaries in Europe, and witnessed how each of them has dealt with the strong transformations that the group has experienced in the last four years. For instance, Mr. Dethlefs from Teva Germany highlighted the challenge in harmonizing five different…

UCB Phrama France Historically, UCB Pharma had a much more ‘traditional’ approach to the industry with a broader scope of operations. Recently, the company reoriented in the direction of biopharmaceuticals by moving away from chemicals and divesting from OTCs. As you have worked on the strategy and policy at headquarters in addition to…

Novo Nordisk France Novo Nordisk just celebrated 50 years in France; what have been some of the more recent events that have marked the affiliate’s time here? If you look from the perspective of the affiliate which includes both our office here in Paris and production center in Chartres then we have doubled…

Baxter France Baxter is approaching 40 years in France, what have been the major milestones of the group during this period and what is the importance of France to the group? During the time we have been present in France there have been key transformations for the company as a whole. Historically,…

France Sandoz has set important trends in the pharmaceutical market, first by creating a leading global generics business under the umbrella of parent company Novartis, and secondly by investing heavily in biosimilars, becoming a pioneer in a fast-growing niche. How have these two steps helped reshape Sandoz internally? With the creation…

Nordic Pharma France Nordic Pharma has been established in the French market since 2002 as one of its first steps towards internationalization. What have been the main milestones and achievements of Nordic in the French market since then? Since our establishment on the French market in 2002, Nordic Pharma has had a number…